Itch Clinical Trial
Official title:
An Open Label Study of Apremilast in Chronic Idiopathic Pruritus
Chronic Itch is a debilitating condition affecting many people. Currently, there are no FDA-approved treatments. Apremilast is an FDA-approved oral medication used to successfully treat the inflammatory skin disorder psoriasis and the inflammatory disorder psoriatic arthritis. This study examines if apremiliast taken twice daily relieves chronic itch.
There is no FDA-approved medication for chronic idiopathic pruritus (CIP). Apremilast has demonstrated notable activity and is approved for treatment in other pruritic inflammatory skin conditions such as psoriasis. The drug is currently being investigated as therapy for atopic dermatitis. Additionally, the investigators have preliminary data to suggest that apremilast's anti-inflammatory properties may work via neuromodulation targeting neuronal cytokine pathways. The proposed study plans to assess the efficacy of apremilast 30 mg BID in the setting of CIP. Durable response to a medication is typically seen within one to two months of starting an efficacious medication in subjects who respond. Therefore, the investigators have designed this study to end at Week 16 to definitively determine efficacy and conclude the study with confidence with regard to both efficacy and failure. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01683552 -
Aprepitant in the Management of Biological Therapies-related Severe Pruritus
|
Phase 2 | |
| Completed |
NCT02075632 -
Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream
|
Phase 2 | |
| Completed |
NCT04515056 -
Characterization of New Human Models of Non-histaminergic Itch
|
N/A | |
| Completed |
NCT04076865 -
Evaluation of the Effect Induced by Repeated Administration of Topical Local Anaesthetic (EMLA) on Itch
|
N/A | |
| Completed |
NCT04588532 -
Characterization of BAM8-22 as a New Surrogate Model of Non-histaminergic Itch
|
N/A | |
| Enrolling by invitation |
NCT05195177 -
Testing Protocol to Efficiently Induce Itch
|
N/A | |
| Withdrawn |
NCT03943407 -
Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% as a New Surrogate Model of Itch
|
N/A | |
| Completed |
NCT04858360 -
Inhibition of Non-histaminergic Pruritus Applied Using 3 Different Pruritogens
|
N/A | |
| Completed |
NCT04635254 -
The Effect of Halophyte-based Cream on Pain and Itch
|
N/A | |
| Not yet recruiting |
NCT06201715 -
Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis
|
N/A | |
| Completed |
NCT06036589 -
Characterization of Bovine Adrenal Medulla as a Model of Non-histaminergic Itch
|
N/A | |
| Not yet recruiting |
NCT06245564 -
Effect of Ketamine, Amitriptyline and Their Combination on Histaminergic and Non-histaminergic Itch
|
N/A | |
| Completed |
NCT04554888 -
Characterization of New Human Models of Non-histaminergic Itch and Their Interaction With the TRPM8 Receptor
|
N/A | |
| Completed |
NCT04387851 -
Learning Mechanisms for Placebo and Nocebo Studies on Somatosensory Sensations: a Systematic Review and Meta-analysis.
|
||
| Completed |
NCT03928223 -
The Color of Itch; Itch Modification by Color Viewing
|
||
| Completed |
NCT03576053 -
A Mechanistic Evaluation of the Interactions Between Thermoceptive and Pruriceptive Sensory Processing
|
N/A | |
| Completed |
NCT04700007 -
Evaluation of Peripheral Itch Mechanisms Following Injection of Morphine (Second Sub-Project)
|
N/A | |
| Terminated |
NCT02828787 -
Central Mechanisms of Chronic Pruritus: Functional and Structural Brain Imaging.
|
N/A | |
| Not yet recruiting |
NCT04197440 -
Characterization of Bovine Adrenal Medulla (BAM8-22) as a New Surrogate Model of Non-histaminergic Itch
|
N/A | |
| Completed |
NCT04115462 -
A Relation of Morphine-induced Itch and Pain Processing
|
N/A |